Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTPO in liver cirrhosis with liver function impairment
NCT03673215Phase 1Unknown
- Sponsor
- 3SBio
- Start
- Jun 2018
- Primary completion
- Oct 2020
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of recombinant human thrombopoietin in Thrombocytopenia (9 arms), sponsored by 3SBio. Primary endpoints: Safety and tolerability as assessed by the collection of adverse events at 29 days, AUC[0-24] of rhTPO at 9 days and 9 more. Status: unknown.
02
Drugs
recombinant human thrombopoietin
03
Conditions
Thrombocytopenia
Beyond the preview
Go deeper on NCT03673215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03673215.